Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05238675 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 322
- Enrollment target
NCT05238675 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 322 participants.
The verdict
NCT05238675, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 322 participants
- Enrollment target
Study Summary
This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 4 groups randomly, which means by chance. Participants in groups 1, 2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the tablets once a day. Participants are in the study for between 6 months and 1 year. During this time, they visit the study site about 10 times and get about 5 phone calls from the site staff. The doctors document when participants experience flare-ups during the study. The time to the first flare-ups is compared between the treatment groups. Doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
- DRUG Placebo
- DRUG BI 1291583
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05238675
The ClinicalTrials.gov registry entry for NCT05238675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05238675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05238675 about?
NCT05238675 is a clinical study titled "A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis". This study is open to adults with bronchiectasis. People can join the study if they produce sputum and have a history of flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into ...
What is the current status of trial NCT05238675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 322 participants. The study started on 2022-04-28. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT05238675?
The interventions under investigation include: Placebo (DRUG), BI 1291583 (DRUG).
Who is sponsoring clinical trial NCT05238675?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.